Greenwich LifeSciences (GLS) is a private biopharmaceutical company located in Houston, TX that is developing GP2, a novel peptide immunotherapy, planning to commence a Phase III trial in 2020, pending funding. In a just completed Phase IIb study, no recurrences have been observed in the Her2/neu 3+ adjuvant setting for up to 5 years, if the patient is fully vaccinated. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including 75% of breast cancers.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):